Completed CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects NCT00277238 Conditions Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more Locations Pfizer Investigational Site — Chicago, Illinois, United States Pfizer Investigational Site — Indianapolis, Indiana, United States Pfizer Investigational Site — New Orleans, Louisiana, United States Pfizer Investigational Site — Detroit, Michigan, United States View all 14 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects NCT00142103 Conditions Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more Locations Pfizer Investigational Site — Miami, Florida, United States Pfizer Investigational Site — Chicago, Illinois, United States Pfizer Investigational Site — Indianapolis, Indiana, United States Pfizer Investigational Site — Detroit, Michigan, United States View all 13 locations View more locations Show fewer locations Loading locations... View Trial Details